A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A phase 1/2 trial of Durvalumab, Carboplatin in small-cell lung cancer, run by IDEAYA Biosciences, now recruiting.
Overview
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07174583 by IDEAYA Biosciences, with 262 participants planned, started 2025-10-14 and due to reach its primary completion in 2029-07. Interventions recorded: IDE849, durvalumab, IDE161, Carboplatin. Conditions listed: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialStudy of AZD2811 + Durvalumab in ES-SCLC
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, Small-cell lung cancer.
- TrialA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, Small-cell lung cancer.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Durvalumab, Carboplatin, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
Shares Durvalumab, Small-cell lung cancer.